ClinicalTrials.gg
Not yet recruitingNCT07950852Updated Nov 20, 2026

Mirogabalin vs. Melatonin for Pain and Anxiety After Total Knee Arthroplasty Under Spinal Anesthesia

A Phase 3 interventional study of Mirogabalin and Melatonin in Knee Arthritis Osteoarthritis, Postoperative Pain and Anxiety, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Beni-Suef University · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 599 studies in Pain, Postoperative with a site in Egypt — 133 open to participants now, 156 under way, 7 of them phase 3. Pain, Postoperative · Egypt.

Planned enrollment
191st of 590
78 · median 60
Started
2026
with 72 others
Phase 3
29 of 599
4 open now
Primary completion
2027-05
later than 129 of 155 live
Registered
597th of 599
by date

Among the 599 studies in Pain, Postoperative with a site in Egypt, this one is the 191st largest by planned enrollment of the 590 interventional ones that give a count, is one of 73 that started in 2026, is one of 29 in phase 3, reaches primary completion later than 129 of the 155 other live ones, and was the 597th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

133 of the 599 studies in Pain, Postoperative with a site in Egypt are open now. Recruiting first, the newest first:

128 more — sign in →

All 133 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 599 studies in Pain, Postoperative with a site in Egypt, or all of them as a file.
02

Study summary

Total knee arthroplasty (TKA) is frequently associated with moderate-to-severe postoperative pain, substantial opioid consumption, and preoperative anxiety. Although spinal anesthesia is preferred for TKA, it does not provide prolonged analgesia after the block resolves.

This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate and compare the efficacy of perioperative oral mirogabalin versus melatonin versus placebo as opioid-sparing analgesic adjuncts in patients undergoing elective unilateral TKA under spinal anesthesia. The primary objective is to assess their impact on postoperative pain intensity and perioperative anxiety levels.

Read the detailed description

Preoperative anxiety affects 30% to 70% of patients undergoing total knee arthroplasty (TKA) and can exacerbate postoperative pain, increase opioid consumption, and delay recovery. Multimodal perioperative optimization within Enhanced Recovery After Surgery (ERAS) protocols is essential to address these challenges.

Mirogabalin is a novel, selective ligand of the α₂δ subunit of voltage-gated calcium channels with a long dissociation half-life, demonstrating analgesic and anxiolytic properties. Melatonin is an endogenous pineal hormone with well-characterized chronobiotic, sedative, anxiolytic, and antinociceptive actions. Despite their potential, no randomized controlled trial has directly compared mirogabalin and melatonin for perioperative optimization in TKA under spinal anesthesia.

Eligible consenting participants (aged 50-70 years, ASA I-III, scheduled for primary elective unilateral TKA under spinal anesthesia) will be randomized (1:1:1) to one of three parallel groups:

  1. Mirogabalin Group: Oral mirogabalin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, 10:00 PM on surgery day, and at 10:00 AM and 10:00 PM on Postoperative Day 1.
  2. Melatonin Group: Oral melatonin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, and 10:00 PM on surgery day; matching placebo at 10:00 AM on Postoperative Day 1, followed by melatonin at 10:00 PM on Postoperative Day 1.
  3. Placebo Group: Matching placebo administered at identical time points.

All patients will receive standardized intraoperative spinal anesthesia (hyperbaric bupivacaine + fentanyl) and standardized background multimodal analgesia (paracetamol, ketorolac, and intraoperative dexamethasone).

Outcomes assessed up to 48 hours postoperatively include Numeric Rating Scale (NRS) pain scores, Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, 24-hour and 48-hour cumulative opioid (nalbuphine) consumption, time to first rescue analgesia, sedation level (MOOA/S), sleep quality (SQS), time to first mobilization, hemodynamic stability, and adverse events.

03

Conditions studied

  • Knee Arthritis Osteoarthritis
  • Postoperative Pain
  • Anxiety

Keywords

  • Mirogabalin
  • Melatonin
  • Total Knee Arthroplasty
  • Spinal Anesthesia
  • Opioid-Sparing Analgesia
  • Preoperative Anxiety
  • Enhanced Recovery After Surgery (ERAS)
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 to 70 years.
  • (ASA) physical status I, II, or III.
  • Scheduled for elective primary unilateral total knee arthroplasty (TKA) under spinal anesthesia.
  • (BMI) between 18.5 and 35 kg/m².
  • Able to understand and complete study questionnaires (APAIS, NRS) in the local language.
  • Provision of signed written .

Exclusion criteria

Exclusion Criteria:

  • to spinal anesthesia (e.g., coagulopathy, local puncture site infection, severe spinal deformity, or patient refusal).
  • Known or allergy to mirogabalin, melatonin, gabapentinoids, or study medication .
  • Pre-existing chronic pain syndrome requiring long-term opioid, gabapentinoid, or melatonin therapy.
  • Severe renal impairment (estimated \< 30 mL/min/1.73 m²) or end-stage renal disease.
  • Severe hepatic impairment ( class C).
  • Psychiatric illness impairing comprehension or cooperation (e.g., dementia, active psychosis) or current treatment with anxiolytics, antipsychotics, or antidepressants.
  • Current pregnancy or breastfeeding.
  • Revision arthroplasty, bilateral TKA procedures, or intraoperative conversion to general anesthesia.
  • Known sleep disorder under active pharmacological treatment, or current shift-work disorder.
  • Participation in another interventional drug trial within 30 days prior to enrollment.
  • Inability to complete visual/numeric pain and anxiety scales due to visual, cognitive, or language barriers.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Group G (Mirogabalin)

    Patients receive oral mirogabalin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on the first postoperative day (Postoperative Day 1). All participants receive standardized spinal anesthesia (hyperbaric bupivacaine 0.5% + fentanyl 25 mcg) and multimodal background analgesia (paracetamol 1 g IV q6h, ketorolac 30 mg IV q12h, and intraoperative dexamethasone 8 mg IV).

    Drug: Mirogabalin

  • Active comparator
    Group M (Melatonin)

    Patients receive oral melatonin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, and 10:00 PM on the day of surgery. On Postoperative Day 1, patients receive a matching placebo tablet at 10:00 AM (to preserve blinding), followed by melatonin 10 mg at 10:00 PM. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

    Drug: Melatonin

  • Placebo comparator
    Group P (Placebo)

    Patients receive matching oral placebo tablets administered at corresponding time points: 10:00 PM the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on Postoperative Day 1. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

    Drug: Placebo Oral Tablet

Interventions

  • Oral mirogabalin 10 mg tablet administered per protocol schedule (5 total doses perioperatively).

  • Oral melatonin 10 mg tablet administered per protocol schedule (4 active doses + 1 placebo dose at 10:00 AM POD 1).

  • DrugPlacebo Oral Tablet

    Matching inert oral placebo tablet administered to Group P (5 total doses) and Group M (1 dose at 10:00 AM POD 1).

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Scores

    Assessed using the Numeric Rating Scale (NRS), where scores range from 0 to 10 (0 = "no pain", 10 = "worst possible pain"). Lower scores represent a more favorable clinical outcome (less pain intensity), whereas higher scores represent an unfavorable outcome.

    Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.

  2. Perioperative Anxiety Scores

    Assessed using the anxiety subscale of the Amsterdam Preoperative Anxiety and Information Scale (APAIS). The anxiety subscale consists of 4 items rated on a 5-point Likert scale (1 = not at all, 5 = extremely), with total anxiety scores ranging from 4 to 20. Lower scores represent a more favorable clinical outcome (lower anxiety), whereas higher scores represent an unfavorable outcome.

    Time frame: Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.

Secondary outcomes

  1. Total Cumulative Postoperative Opioid Consumption

    Total intravenous nalbuphine consumption measured in milligrams (mg) administered as rescue analgesia during the first 24 and 48 postoperative hours. Lower cumulative dose values represent a more favorable outcome (greater opioid-sparing effect).

    Time frame: First 24 and 48 hours postoperatively.

  2. Time to First Request for Rescue Analgesia

    Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU, time zero) to the first administration of rescue IV nalbuphine for NRS pain score \>= 4. Longer duration (higher values in minutes) represents a more favorable outcome (prolonged postoperative analgesia).

    Time frame: Up to 48 hours postoperatively.

  3. Postoperative Sedation Scores

    Evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOOA/S) scale, ranging from 0 (does not respond to deep algic stimulus) to 5 (responds readily to name spoken in normal tone). A score of 5 represents alertness (favorable recovery state), whereas lower scores indicate deeper sedation (unfavorable/excessive drug-induced sedation).

    Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.

  4. Incidence of Postoperative Nausea and Vomiting and Requirement for Rescue Antiemetics

    Number of participants experiencing nausea or vomiting and requiring rescue antiemetic therapy. A lower incidence (fewer participants affected) represents a favorable outcome.

    Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.

  5. Postoperative Sleep Quality Score

    Assessed using the Single-Item Sleep Quality Scale (SQS), where overall sleep quality over the 48-hour postoperative period is rated on a 0 to 10 scale (0 = terrible, 10 = excellent). Higher scores represent a more favorable outcome (better sleep quality).

    Time frame: Assessed at 48 hours postoperatively.

  6. Time to First Postoperative Mobilization

    Time elapsed (in hours) from arrival in the PACU to first achieving bedside sitting and subsequent assisted ambulation. Shorter duration (lower values in hours) represents a more favorable recovery outcome.

    Time frame: Up to 48 hours postoperatively.

  7. Incidence of Treatment-Emergent Adverse Events

    Number of participants experiencing adverse drug events, including dizziness, excessive somnolence, headache, pruritus, constipation, and urinary retention. A lower incidence represents a more favorable safety profile.

    Time frame: Up to 48 hours postoperatively.

  8. Incidence of Intraoperative Hypotension and Bradycardia

    Number of participants experiencing spinal-anesthesia-related hypotension (mean arterial pressure drop \> 20% from baseline requiring IV fluids/ephedrine) or bradycardia (heart rate \< 50 bpm requiring IV atropine). A lower incidence represents a more favorable hemodynamic stability profile.

    Time frame: Intraoperatively (from spinal injection to completion of surgery).

  9. Patient Satisfaction With Perioperative Analgesia

    Evaluated on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores represent a more favorable outcome.

    Time frame: Assessed at 24 hours postoperatively.

  10. Length of Postoperative Hospital Stay

    Duration of hospital stay measured in hours from completion of surgery until meeting formal discharge criteria. Shorter stay duration (lower values) represents a more favorable outcome.

    Time frame: From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results (including baseline demographics, intervention group allocation, pain scores, anxiety scores, cumulative opioid consumption, and adverse event data) will be made available to qualified researchers upon reasonable request to the

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months and ending 3 years following article publication

Access criteria: Available to academic researchers who provide a methodologically sound proposal approved by the Beni-Suef University Research Ethics Committee

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 6 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950852
Responsible party
Kerollos Moneer Neseem Mikhael (Lecturer of Anesthesiology, Surgical Intensive care and Pain Management, Beni-Suef University) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Kerollos Moneer Neseem Mikhael, MD
Contact
Kmnmk87@med.bsu.edu.eg
00201288549959

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirogabalin

Start the discussion